Press Releases

    Print Page  Close Window
BioMed Realty Trust Enters Into Leases With Illumina, Inc. Totaling 195,000 Square Feet

SAN DIEGO, Feb. 20 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that it has signed new, long-term leases with Illumina, Inc., a public company focused on developing next-generation tools for the large-scale analysis of genetic variation and function, for approximately 195,000 square feet of office and laboratory space at the company's Towne Centre Drive property in San Diego, California.

Under the new leases, Illumina will expand into a new 84,000 square foot state-of-the-art building to be constructed by BioMed at the property. BioMed expects to complete construction in the third quarter of 2008. Once completed and occupied, Illumina will lease the new building for a 15-year term. In addition, Illumina extended its lease for the 109,270 square feet it currently occupies at Towne Centre Drive by nine years to 2023 to correspond with the new 15-year lease.

"We are excited to be able to accommodate Illumina's growing need for additional laboratory and office space with what will be a high-quality class A property designed to meet their needs," said Alan D. Gold, President and Chief Executive Officer of BioMed Realty Trust. "This transaction further exemplifies our strategy of pre-leasing and constructing new laboratory and office space on our undeveloped land, and our mission of being the leading provider of real estate to the life science industry in each of our core markets."

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(TM). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry, and its properties are generally located in markets with well established reputations as centers for scientific research, including Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey. BioMed's real estate portfolio consists of 56 properties, representing 92 buildings with approximately 7.9 million rentable square feet in each of the major life science markets in the United States. Additional information is available at

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE BioMed Realty Trust, Inc.

CONTACT: Kent Griffin, Chief Financial Officer of BioMed Realty Trust,
Inc., +1-858-485-9840
Web site: